Eszopiclone

Generic Name: Eszopiclone

Brand Names: Lunesta

Drug Type: Small Molecule

Chemical Formula: C_₁₇H_₁₇ClN_₆O_₃

CAS Number: 138729-47-2

Unique Ingredient Identifier: UZX80K71OE

Background: Eszopiclone, marketed by Sepracor under the brand-name Lunesta, is a nonbenzodiazepine hypnotic drug used to treat insomnia. It is the active stereoisomer of zopiclone, belonging to the class of drugs known as cyclopyrrolones. Cyclopyrrolone drugs demonstrate high efficacy and low toxicity, offering a safer alternative to other drugs used for insomnia.
...

Indication: Eszopiclone is indicated for the treatment of insomnia.

Associated Conditions: Insomnia

Associated Therapies: -

Clinical Trials

Eszopiclone for the Treatment of Posttraumatic Stress Disorder

Phase 4

Completed

Conditions: Posttraumatic Stress Disorders

Interventions: Drug: Placebo
Drug: Eszopiclone

First Posted Date: 2012-05-24

Last Posted Date: 2022-12-23

Lead Sponsor: Rush University Medical Center

Target Recruit Count: 81

Registration Number: NCT01605253

Locations: 🇺🇸
Center for Anxiety and Traumatic Stress Disorders at Rush, Chicago, Illinois, United States

The Effect of Eszopiclone on the Arousal Threshold in Sleep Apnea Syndrome

Early Phase 1

Completed

Conditions: Obstructive Sleep Apnea

Interventions: Drug: Eszopiclone
Drug: Placebo

First Posted Date: 2010-04-13

Last Posted Date: 2017-04-18

Lead Sponsor: Brigham and Women's Hospital

Target Recruit Count: 17

Registration Number: NCT01102270

Locations: 🇺🇸
Brigham and Women's Hospital, Division of Sleep Medicine, Boston, Massachusetts, United States

A Non-inferiority Study With Two Treatment Arms Eszopiclone 3 mg Versus Zopiclone 7.5 mg - for the Treatment of Insomnia

Phase 3

Completed

Conditions: INSOMNIA

Interventions: Drug: Eszopiclone
Drug: Zopiclone

First Posted Date: 2010-04-08

Last Posted Date: 2015-07-27

Lead Sponsor: Eurofarma Laboratorios S.A.

Target Recruit Count: 263

Registration Number: NCT01100164

Locations: 🇧🇷
CRDB - Clinical Research & Development Brazil, São Paulo, Brazil

Effects of Daytime Eszopiclone Administration in Shift Workers

Not Applicable

Completed

Conditions: Shift-Work Sleep Disorder

Interventions: Drug: eszopiclone
Drug: matching placebo

First Posted Date: 2009-05-12

Last Posted Date: 2017-08-30

Lead Sponsor: Brigham and Women's Hospital

Target Recruit Count: 24

Registration Number: NCT00900159

Locations: 🇺🇸
Brigham & Women's Hospital, Boston, Massachusetts, United States

The Effect of Marijuana and Prescription Medications in Mood, Performance and Sleep

Phase 1

Completed

Conditions: Marijuana Dependence

Interventions: Drug: eszopiclone
Drug: Placebo
Drug: ramelteon
Drug: zolpidem

First Posted Date: 2009-05-05

Last Posted Date: 2013-12-05

Lead Sponsor: Johns Hopkins University

Target Recruit Count: 36

Registration Number: NCT00893269

Locations: 🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States

Eszopiclone Treatment & Cortisol Responsivity

Phase 4

Completed

Conditions: Insomnia

Interventions: Drug: eszopiclone

First Posted Date: 2009-04-28

Last Posted Date: 2017-09-08

Lead Sponsor: Butler Hospital

Target Recruit Count: 12

Registration Number: NCT00889200

Locations: 🇺🇸
Butler Hospital, Providence, Rhode Island, United States

Safety & Efficacy Study of Study Drug (Eszopiclone) in Children and Adolescents With Attention-deficit/Hyperactivity Disorder - Associated Insomnia

Phase 3

Completed

Conditions: Insomnia
Attention Deficit Hyperactivity Disorder

Interventions: Drug: Placebo
Drug: eszopiclone

First Posted Date: 2009-03-06

Last Posted Date: 2013-06-17

Lead Sponsor: Sumitomo Pharma America, Inc.

Target Recruit Count: 486

Registration Number: NCT00856973

Locations: 🇺🇸
Tulsa Clinical Research, Tulsa, Oklahoma, United States
🇺🇸
SomnoMedics, LLC, Tampa, Florida, United States
🇺🇸
Pediatric Epilepsy and Neurology Specialists, Tampa, Florida, United States

and more 66 locations

Long Term Safety Study of Study Drug (Eszopiclone) in Children and Adolescents With ADHD -Associated Insomnia

Phase 3

Completed

Conditions: Insomnia
Attention Deficit Hyperactivity Disorder

Interventions: Drug: eszopiclone

First Posted Date: 2009-03-06

Last Posted Date: 2017-10-26

Lead Sponsor: Sumitomo Pharma America, Inc.

Target Recruit Count: 304

Registration Number: NCT00857220

Locations: 🇺🇸
Clinical Research Center of Nevada, Henderson, Nevada, United States
🇺🇸
Davis Clinic, Indianapolis, Indiana, United States
🇺🇸
Goldpoint Clinical Research, LLC, Indianapolis, Indiana, United States

and more 82 locations

Effects of Eszopiclone on Sleep-dependent Learning in Schizophrenia

Not Applicable

Completed

Conditions: Schizophrenia

Interventions: Drug: placebo
Drug: eszopiclone

First Posted Date: 2009-02-02

Last Posted Date: 2014-09-09

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 25

Registration Number: NCT00833547

Locations: 🇺🇸
Mass General Hospital, Boston, Massachusetts, United States

The Effects of Eszopiclone and Lexapro on Prefrontal Glutamate and GABA in Depression With Anxiety and Insomnia

Phase 4

Completed

Conditions: Depression
Anxiety
Insomnia

Interventions: Drug: Eszopiclone
Drug: Placebo

First Posted Date: 2009-01-21

Last Posted Date: 2012-06-29

Lead Sponsor: Steward St. Elizabeth's Medical Center of Boston, Inc.

Target Recruit Count: 19

Registration Number: NCT00826111

Locations: 🇺🇸
Steward St. Elizabeth's Medical Center of Boston, Inc., Boston, Massachusetts, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy